OX40/OX40L antagonists (e.g., Oxelumab, Amlitelimab, Cudarolimab, Vonlerolizumab, Rocatinlimab) have demonstrated efficacy in atopic dermatitis, asthma, and ulcerative colitis, with notable therapeutic success in atopic dermatitis (141). Here, TNFRSF4 is linked to atopic eczema.